Found some tickers I want to share with y'all. This is a continuation of my last recent blog/watch list, blog here.


AzurRx BioPharma, Inc. (NASDAQ: $AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819-SD, a recombinant lipase for exocrine pancreatic insufficiency, is the Company's lead development program, and additional early stage research is being conducted for the prevention of certain hospital-acquired infections.  The Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on AzurRx can be found at

Drug: MS1819 (OPTION)

  • Phase 2 data due late-summer 2019.

    The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1103, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France. 

    Due Diligence:

    1. 16.23M FLOAT 
    2. Closing of $5 Million Public Offering of Common Stock, on 07/11/2019. 
    3. Reported $413.8K Cash as of March 31, 2019. 
    4. In June 2018, the Company completed an open-label, dose escalation Phase IIa trial of MS1819-SD in France, Australia, and New Zealand (From 10-Q SEC Filing).
    The bad: 

    o Made an initial payment to Mayoly of €800,000, which amount was paid by the issuance of 400,481 shares of the Company’s common stock at a price of $2.29 per share. 

    o Agreed to pay to Mayoly an additional €1,500,000, payable in a mix of cash and shares of the Company’s common stock


    Curis ($CRIS) is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene to develop first-in-class therapeutics in immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with mesothelioma and in a Phase 2 trial in patients with advanced solid tumors and lymphomas in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at

     Drug: CA-4948 for Relapsed or Refractory Non-Hodgkin Lymphoma 

    • Phase 1 data due mid-2019 
    The Company is currently evaluating CA-4948 in an ongoing Phase 1 trial in patients with non-Hodgkin lymphoma, including those with MYD88 alterations, with interim data expected in mid-2019. In addition, the Company is further investigating the potential of CA-4948 in patients with myeloid malignancies expressing IRAK4-L and with U2AF1 mutations. Article here.


    Due Diligence: 

    1. 42.8M Cash on hand 
    2. 24.49M FLOAT 
    3. 17.28% Held by Insiders / 24.15% Institutions 
    4. Fimepinostat has FDA Fast Track Designation 
    5. Other drugs in pipeline.


    Quick Momentum play: $PTN (0.83/0.87) Looking to break SMA at 1.00/1.05, I am in with 0.85 avg.


    DISCLAIMER: Not a financial advisor. Just sharing my opinion on potential price action if volume comes in. Opinions are my own, please do your due diligence. Do this out of passion!

    Leave a comment